Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter's Option to Purchase Additional Shares
A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.
Investors/Media:
Jim Welch
Phone: (650) 279-9845
Email: [email protected]
View original content with multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-300546791.html
SOURCE